NanoCell Therapeutics' NCtx Platform Could Revolutionize CAR-T Therapy Accessibility

NanoCell Therapeutics, Inc. has unveiled research data in the Journal for ImmunoTherapy of Cancer, showcasing its NCtx platform's ability to generate chimeric antigen receptor T-cells (CAR-T) directly in vivo. This innovation could significantly lower the barriers to CAR-T therapy, which currently costs around $300,000 per patient and requires complex manufacturing processes. The NCtx platform utilizes targeted lipid nanoparticles to deliver DNA encoding a CAR construct and transposase mRNA, enabling stable genomic integration and durable CAR expression with just a single injection. The study highlights the platform's potential to transform cancer treatment by simplifying protocols and expanding access to patients globally.

The research, conducted in collaboration with the Shanghai Cell Therapy Group and supported by the European Union's Horizon programs, demonstrated successful CAR-T cell generation in humanized mouse models. These cells showed effective tumor control and prolonged survival, even at low doses. NanoCell Therapeutics' CEO, Dr. Maurits Geerlings, emphasized the platform's modular design, which allows for rapid adaptation to various therapeutic targets, promising a broad impact across oncology and autoimmune diseases. With plans to pursue an IMPD application, NanoCell is moving closer to clinical development, marking a pivotal step toward realizing the platform's potential.